Objective: The distribution of Leu7Pro polymorphism in the neuropeptide Y gene shows a geographical north to south gradient of decreasing frequency, suggesting that it may be a population-specific causal variant. This polymorphism is found to be associated with diabetic nephropathy (DN) and coronary heart disease in Finnish women with type 1 diabetes (T1D). The present study aims to evaluate the susceptibility of this polymorphism to the development of DN in two different populations. Design: One sample set consists of 174 (females 98 and males 76) Swedish T1D patients with DN and 249 (females 132 and males 117) patients without DN. Another sample set includes 597 (females 356 and males 241) American T1D patients without DN and 577 (females 264 and males 313) patients with DN, who were descents of European Caucasians and were from the Genetics of Kidneys in Diabetes (GoKinD) Study. Methods: Genotyping of Leu7Pro polymorphism was performed by dynamic allele-specific hybridization. Results: The C allele frequencies of Leu7Pro polymorphism in T1D patients between Swedish and American GoKinD populations were significantly different (6.3 vs 4.0%; PZ0.006). Particularly, the C allele frequency in Swedish female T1D patients with DN was significantly higher in comparison with T1D patients without DN (10.2 vs 4.2%; PZ0.011, ORZ2.614, 95% confidence intervals: 1.249-5.467). No significant association of this polymorphism with DN was observed in Swedish male T1D patients and the patients from GoKinD.
Introduction
The patients with type 1 diabetes (T1D, online Mendelian inheritance in man (OMIM) 222100) often develop serious long-term complications including diabetic nephropathy (DN). DN leads to renal failure and is also associated with a high risk of coronary artery disease and other vascular complications. The development of DN is influenced by genetic and environmental factors. Thus, identification of the polymorphisms in the susceptibility genes associated with DN could enable earlier detection of these complex diseases. An understanding of the role of the susceptibility genes in DN will ultimately allow the development of novel therapeutic strategies (1) .
Neuropeptide Y (NPY, OMIM 162640) is a 36-amino acid polypeptide that is present in the central and peripheral nervous systems, several peripheral organs, and plasma (2) (3) (4) (5) . Both in vivo and in vitro studies have demonstrated that NPY inhibits glucose-stimulated insulin secretion (6, 7) . NPY has also been shown to regulate renal blood flow (8) . Stimulation of the NPY receptors in the kidney, using active agonists, may decrease glomerular filtration rate, aldosterone concentration, and plasma renin activity, but increase sodium excretion in the kidney (9) . A clinical study indicates that plasma immunoreactive (IR)-NPY and urinary IR-NPY concentrations are elevated in type 2 diabetic (T2D) patients with advanced nephropathy (10) . Several studies, using T1D animal models such as the streptozotocin-diabetic rats, have demonstrated that NPY release is increased in the hypothalamus (11, 12) . The evidence implies that NPY may play a role in the pathogenesis of diabetes and DN.
The NPY gene is located in chromosome 7p15.1. There is a unique detectable non-synonymous single nucleotide polymorphism (SNP), i.e. Leu7Pro (T1128C) found in the coding region of the gene (13) . The consequence of Pro7 substitution on prepro-NPY is not fully understood, but the Pro7 may have an impact on NPY processing, circulating NPY levels, growth hormone secretion, and serum cholesterol and triglyceride levels (13) (14) (15) (16) (17) . Interestingly, the polymorphism exists with a relatively high frequency in Finnish and Swedish populations but low frequency in other ethnic populations (18, 19) . In the past 7 years, several genetic studies indicate that polymorphism is associated with the development of T2D (20) , retinopathy (21, 22) , and enhanced carotid atherosclerosis (23) . Moreover, there is a report indicating that Leu7Pro polymorphism confers susceptibility to the development of nephropathy and coronary heart disease (CHD) in Finnish female T1D patients (24) . In the present study, we have conducted a genetic association analysis of the polymorphism in two populations including Swedish and American T1D patients with or without DN. The aim is to evaluate the susceptibility of NPY Leu7Pro polymorphism to the development of DN in these two populations.
Design and methods

Subjects
The clinical material in the present study consists of two sample sets from Swedish and American populations. All T1D patients were diagnosed according to the World Health Organization criteria (25) . The studies were approved by the local ethics committees. Informed consents were obtained from all the subjects studied. Clinical characteristics of the subjects from Swedish and American populations are summarized in Table 1 .
The first sample set included 174 (females 98 and males 76) T1D patients with DN and 249 (females 132 and males 117) patients without DN. All patients were Swedish Caucasians. All T1D patients had the urinary albumin excretion rates (UAER) measured. The patients without DN had UAER of !20 mg/min. One hundred T1D patients with microalbuminuria (incipient nephropathy) had UAER of 20-200 mg/min in at least two out of three consecutive overnight samples. Seventy-four patients with macroalbuminuria (overt nephropathy) had UAER of O200 mg/min (the cases with end-stage renal disease (ESRD), not due to the condition other than diabetes, were included in the patients with overt nephropathy but the number is limited). The patients with DN had retinopathy as well. Non-diabetic kidney diseases and ESRF were excluded. T1D patients with DN had no treatment using ACE inhibitors.
The second sample set had 597 (females 356 and males 241) American T1D patients without DN and 577 (females 264 and males 313) patients with DN, who were from the Genetics of Kidneys in Diabetes (GoKinD) Study (26) . All patients were descents of European Caucasians. The T1D patients were diagnosed before the age of 31 years. Treatment with insulin was instituted within 1 year of diagnosis, and treatment with insulin has been uninterrupted since diagnosis. The patients with DN had persistent proteinuria for at least 10 years or ESRD (nZ408, not due to the condition other than diabetes). Persistent proteinuria was defined as two out of three tests positive for albuminuria (at least 1 month apart), i.e. dipstick (Albustix or Multistix) at least 1C or urine albumin/ urine creatinine ratio (ACR) value exceeding 300 mg albumin/mg of urine creatinine. The patients without DN had persistent normoalbuminuria despite duration of T1D for at least 15 years and had never been treated with ACE inhibitors. Persistent normoalbuminuria was defined as at least two out of three ACR measurements (at least 1 month apart) in random urine specimens being !20 mg albumin/mg of urine creatinine. If three ACR measurements were needed, the highest must also be !40 mg albumin/mg of urine creatinine. Other kidney diseases in these cases were excluded. 
PCR-DASH genotyping
Genomic DNA was extracted from peripheral blood using a Puregene DNA purification kit (Gentra System, Minneapolis, MN, USA Table 2 . In all of the T1D patients with and without DN among Swedish population, the C allele frequency was 7.1%, which was significantly higher than that in all American T1D patients (4.0%; PZ0.006 and P c Z0.012 with Bonferroni correction for multiple comparisons). Analyses of allelic association indicated that the C allele frequencies between Swedish female T1D patients with and without DN were different (10.2 vs 4.2%; PZ0.011 and P c Z0.022 with Bonferroni correction). A similar comparison analysis between Swedish male T1D patients with and without DN was done; however, the C allele frequencies were found to be similar (5.3 and 6.0%; PZ0.766). Table 2 demonstrated the genotype distribution and the C allele frequencies of male and female American T1D patients with and without DN. In the collected subjects of GoKinD, w8% of total subjects were Americans of Black, Asian, Hispanic, or Indian descents. In order to avoid the error caused by the subjects from different races, those patients were excluded from the analyses. Analyses between T1D patients with and without DN, who were descents of European Caucasians in the American population, were conducted. Data indicated that male and female T1D patients with DN had similar frequencies of the C allele in NPY Leu/Pro polymorphism (4.5 and 4.0%) in comparison with the male and female T1D patients without DN (3.3 and 3.9%; PZ0.326 and 0.968 respectively). We further performed a multivariate logistic regression analysis to predict the susceptibility to DN. Table 3 shows that Leu7Pro polymorphism was strongly associated with DN in Swedish female T1D patients (PZ0.039, ORZ3.379, 95% CI: 1.061-10.768), when variables of duration, HbA1c, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were included in the model. Since SBP and DBP between the patients with DN and without DN in both male and female were found to be significantly different, the similar test for Swedish male T1D patients with and without DN was also performed. No statistically significant association with DN in Swedish male T1D patients was detected (data not shown).
Discussion
We have conducted a genetic association study of NPY Leu7Pro polymorphism in T1D patients with and without DN among Swedish and American populations. We found the C allele frequency of this polymorphism in T1D patients with and without DN among Swedish population was higher than that in American population. Furthermore, we found that polymorphism was significantly associated with DN in Swedish female T1D patients.
The previous studies have demonstrated that the C allele of Leu7Pro polymorphism showed a decreasing frequency with the geographical distribution from north to south gradient. The highest C allele frequency was found in Finnish and the second highest in Swedish (13, (18) (19) (20) . Furthermore, Pettersson-Fernholm et al. reported that Leu7Pro polymorphism in Finnish T1D patients had the C allele frequency of 7.5%, and the C allele had the risk susceptibility for DN and CHD in female but not in male patients with T1D (24) . Results from the present study indicate that the C allele frequency of Leu7Pro polymorphism in Swedish T1D patients is 6.3%, which is slightly lower than that in Finnish T1D patients (24) but significantly higher in comparison with American T1D patients (4.0%). Importantly, we found that the C allele of Leu7Pro polymorphism was significantly associated with female T1D patients with DN among Swedish population. The association remains significant after Bonferroni correction for multiple comparisons. Clinical evidence demonstrates that female T1D patients with DN have reduced circulating levels of estradiol and have imbalance in the expression of estrogen receptor subtypes (26) . The female T1D patients who develop microalbuminuria are younger than the corresponding male subjects (27, 28) . In the recent years, we have used positional candidate gene approach to detect the susceptibility genes in DN. In addition to the present study, we have found that several candidate genes, for instance, adiponectin, confer the genetic susceptibility in female T1D patients with DN (Zhang et al. unpublished data). Therefore, we suggest that there are gender-specific effects of the genetic risk for DN. However, T1D and DN are complex diseases. To dissect the complexity and fully explain the mechanism behind, it is necessary to investigate more genes and also to elucidate the biological basis of genegender interactions in the etiology of these diseases.
We analyzed the data for the subjects in Swedish and American GoKinD populations separately in order to avoid a type 2 error caused by different genetic backgrounds from different ethnic groups. In the GoKinD population, all studied patients are highly selected from American T1D population, and they are descents of European Caucasians but may not be from Sweden or Finland. We found that the frequencies of allele C in T1D patients with and without DN were low, and no significant association between Leu7Pro polymorphism and DN was detectable. Moreover, 34.7% of the patients had ESRD. We attempted to detect the association between Leu7Pro polymorphism and ESRD, and no statistically significant results were found.
Taken together the present study and previous reports, we thus conclude that NPY Leu7Pro polymorphism distributes with higher C allele frequency in Swedish population. This polymorphism confers the susceptibility to the development of DN in Swedish female T1D patients, and its susceptibility may interact with environmental factors in the northern geographical area. Question concerning gender specificity related to genetic influence has been taken into our consideration. 
